Home › Castration-Resistant Prostatic Cancer › Illinois
Castration-Resistant Prostatic Cancer clinical trials in Illinois
3 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in Illinois.
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Duly Health and Care, Lisle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07225946A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Chicago Medical Center, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- University of Chicago Medical Center, Chicago
RecruitingPhase 1
Ages 18 to 100 · Men · Updated Aug 13, 2026 · NCT05519449From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.